In a groundbreaking study poised to reshape the landscape of cancer therapeutics, researchers have unveiled a novel resistance mechanism in colorectal cancer that challenges the efficacy of KRAS inhibitor treatments. Published in Nature Communications in 2026, the research led by Guo, Zhong, Hu, and their colleagues uncovers how colorectal tumors can circumvent the cytotoxic effects of KRAS pathway inhibition by dynamically rewiring the mevalonate pathway through enhancer remodeling. This discovery shines a light on the intricate molecular circuitry cancer cells exploit to sustain their malignancy and reveals a new frontier for therapeutic intervention.

KRAS mutations, long recognized as critical drivers in various cancers, have been notoriously difficult to target effectively. Recent advances in small molecule inhibitors have enabled direct targeting of mutant KRAS proteins, offering new hope particularly for colorectal cancer patients harboring these mutations. However, clinical trials revealed an emerging pattern of resistance, with tumors rapidly adapting and resuming growth despite continuous KRAS inhibition. The study’s authors set out to decipher the molecular underpinnings that empower tumors to resist these once-promising agents.

At the core of their discovery lies the mevalonate pathway, a critical metabolic cascade responsible for producing sterols, isoprenoids, and other essential biomolecules involved in cell membrane integrity, protein prenylation, and cell signaling. Intriguingly, the research demonstrates that colorectal cancer cells, when faced with blockade of KRAS signaling, undergo profound enhancer remodeling — epigenetic and chromatin-based changes that rewire gene regulatory elements — which in turn upregulates components of the mevalonate pathway. This adaptive metabolic shift not only compensates for the inhibited KRAS activity but also fuels continued tumor cell survival and proliferation.

Utilizing state-of-the-art epigenomic profiling techniques, including ATAC-seq and ChIP-seq, the investigators mapped dynamic changes in enhancer landscapes in colorectal tumors subjected to KRAS inhibitor treatment. Their data reveal a robust activation of enhancers associated with key mevalonate pathway genes, correlating with increased transcriptional output. These enhancer regions exhibit hallmark features of activation, such as heightened H3K27ac marks, underscoring the tumor’s epigenetic plasticity as a driving force behind therapeutic resistance.

The functional consequences of mevalonate pathway enrichment were explored through comprehensive metabolomic and lipidomic analyses. Cancer cells demonstrated elevated levels of cholesterol, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate—metabolites critical for post-translational modification of signaling proteins, including small GTPases beyond KRAS itself. This suggests that the tumor’s metabolic flexibility allows bypassing of blocked KRAS signaling by fostering alternative prenylation-dependent oncogenic pathways, sustaining malignant phenotypes.

Crucially, pharmacological inhibition of enzymes within the mevalonate pathway, such as HMG-CoA reductase, in combination with KRAS inhibitors, reversed resistance and significantly impaired tumor growth in preclinical colorectal cancer models. These findings pave the way for novel combinatorial therapeutic strategies that target both signaling and metabolic axes, potentially transforming current clinical management of KRAS-mutant colorectal cancer.

The implications of enhancer remodeling driven metabolic rewiring extend beyond colorectal cancer. Given the prevalence of KRAS mutations across multiple tumor types, similar adaptive resistance mechanisms may underlie therapeutic failure in lung and pancreatic cancers treated with KRAS inhibitors. This highlights the imperative to integrate epigenomic and metabolic profiling in future clinical trials to identify biomarkers predictive of resistance and optimize treatment regimens.

At a molecular level, enhancer remodeling involves recruitment and redistribution of transcription factors and coactivators, altering chromatin accessibility landscapes. The study identifies key players such as BRD4 and the histone acetyltransferase p300 as facilitators of enhancer activation at mevalonate pathway loci. Targeting these epigenetic modulators with BET inhibitors or HAT inhibitors demonstrated partial restoration of KRAS inhibitor sensitivity, providing additional therapeutic avenues.

This research underscores the complexity of cancer resistance, reinforcing the concept that tumor cells can co-opt fundamental biological processes—such as epigenetic regulation and metabolic flux—to evade targeted therapies. It exemplifies the necessity of multidimensional therapeutic interventions that concurrently address both genetic drivers and adaptive cellular states.

Moreover, the study emphasizes the evolving role of advanced genomic and epigenomic technologies in oncology research. The integration of enhancer landscape mapping with metabolic profiling creates a powerful framework for uncovering hidden resistance pathways. This systems biology approach will be crucial to staying one step ahead of cancer evolution and therapeutic evasion.

In conclusion, the elucidation of mevalonate pathway rewiring driven by enhancer remodeling as a mechanism conferring resistance to KRAS inhibitors represents a major leap in our understanding of colorectal cancer biology. It advocates for the development of combination therapies that strategically target interconnected oncogenic networks. Future clinical trials incorporating inhibitors of both the KRAS signaling axis and mevalonate metabolism hold promise for overcoming resistance and improving patient outcomes.

As the war against cancer advances into new terrain, studies like this reveal the adaptive ingenuity of tumor cells and the sophisticated molecular arms race that defines modern oncology. By illuminating these concealed survival tactics, researchers provide both a warning and a beacon—resistance is inevitable, but so too is the potential for innovative solutions grounded in deep mechanistic insight.

The road ahead demands close collaboration between basic scientists, clinicians, and pharmaceutical developers to translate these insights into effective therapies. Precision oncology is entering an era where epigenetic and metabolic plasticity are recognized as central determinants of therapeutic success. Understanding and targeting these dynamic cellular programs will be key to achieving durable remissions in KRAS-mutant colorectal cancer and beyond.

---

Subject of Research: Resistance mechanisms in colorectal cancer involving mevalonate pathway rewiring and enhancer remodeling under KRAS inhibitor treatment.

Article Title: Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Article References:
Guo, Y., Zhong, Y., Hu, P. et al. Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73805-7

Image Credits: AI Generated

Some effects can be traced to chemical signals inside appetite neurons.

A new AI framework called MouseMapper allows scientists to examine disease-related changes across the entire body at cellular resolution. Obesity does much more than affect metabolism and fat storage. It also changes immune activity, nerve structure, and tissue organization throughout the body, raising the risk of conditions such as type 2 diabetes, cardiovascular disease, stroke, [...]

Scientists identified phosphatidylcholine loss as a key driver of mitochondrial aging and showed that restoring it can rejuvenate cellular energy networks. Why do cells age, and why do people gradually lose energy and vitality over time? Scientists have long focused on mitochondria, the tiny structures inside cells responsible for producing energy. Researchers now understand that [...]

In a groundbreaking advancement in metabolic medicine, researchers at the Medical University of Vienna have utilized an innovative whole-body positron emission tomography/computed tomography (PET/CT) imaging framework to reveal the extensive metabolic transformation triggered by bariatric surgery. This state-of-the-art imaging technique, employing radiolabeled glucose analog [18F]fluorodeoxyglucose (18F-FDG), has illuminated the profound metabolic remodeling across numerous organs, offering unparalleled insights into how bariatric surgery reshapes the body’s internal metabolic landscape beyond mere weight loss.

For decades, bariatric surgery has served as a cornerstone treatment for obesity, delivering sustained weight reduction and mitigating related comorbidities such as diabetes and cardiovascular disease. However, until now, the precise systemic metabolic changes induced by these surgical interventions remained largely elusive. The advent of this novel PET/CT-based investigative approach addresses this gap by simultaneously quantifying metabolic activity across a broad spectrum of tissues, highlighting coordinated organ responses that contribute to metabolic recovery.

The study retrospectively analyzed 32 individuals diagnosed with obesity, who underwent either laparoscopic sleeve gastrectomy or one-anastomosis gastric bypass—a pair of commonly employed bariatric procedures. Whole-body 18F-FDG PET/CT scans were performed preoperatively and again at a 12-month postoperative interval. This design allowed for a comprehensive comparison of metabolic alterations in diverse tissues including subcutaneous and visceral adipose depots, liver, pancreas, spleen, adrenal glands, and skeletal muscle.

Quantitative analysis of 18F-FDG uptake demonstrated a significant decline in glucose metabolism within adipose tissue compartments—both subcutaneous and visceral—as well as in the liver, pancreas, and spleen. These reductions reflect diminishing metabolic stress and inflammatory activity, consistent with clinical improvements reported in patients’ glycemic control and lipid profiles. Intriguingly, skeletal muscle metabolism exhibited complex remodeling, potentially indicating enhanced insulin sensitivity and muscle functionality after weight loss surgery.

Perhaps most striking was the observation of an apparent increase in colonic volume at the 12-month mark, pointing to a potential compensatory adaptation in gastrointestinal anatomy and function. This expansion may influence nutrient absorption dynamics and warrants further investigation. Moreover, the network analysis of PET data revealed increased metabolic connectivity between different organs post-surgery, signifying a more synchronized, systemic metabolic state rather than isolated organ changes.

These multidimensional metabolic insights provide compelling evidence that bariatric surgery unleashes a holistic metabolic recalibration, underscoring the notion that organ systems adapt in concert to restore metabolic homeostasis. This data challenges the traditional focus on singular biomarkers and weight parameters by emphasizing integrative organ-level metrics that better capture the complexity of obesity treatment outcomes.

Clinicians stand to benefit immensely from these findings, as whole-body molecular imaging could serve as a vital tool for tailoring postoperative care. By visualizing metabolic recovery across multiple tissues, healthcare providers can optimize monitoring strategies, anticipate complications, and customize therapeutic interventions—transitioning from a one-size-fits-all paradigm toward truly personalized metabolic medicine.

While pharmacological advances, such as glucagon-like peptide 1 (GLP-1) receptor agonists, have recently gained prominence in managing obesity, many patients continue to elect bariatric surgery for its durable benefits and reduced reliance on chronic medication. The novel imaging approach described herein holds promise for enhancing the safety and efficacy of these surgical treatments by illuminating the intricate biological shifts occurring during the critical healing and adaptation periods.

From a technological perspective, relying on 18F-FDG PET/CT imaging leverages the high sensitivity of positron emission tomography combined with anatomical precision from computed tomography, enabling precise spatial localization and quantification of metabolic signals. This synergistic imaging modality opens pathways for broader applications beyond obesity, including the study of metabolic diseases, cancer metabolism, and aging.

The researchers emphasize that interpreting postoperative metabolic changes necessitates multifactorial analysis, integrating PET imaging results with comprehensive laboratory assessments of glycemic indices, lipid panels, endocrine markers, and inflammatory parameters. Such a multidisciplinary approach is essential to unravel the complex biochemical networks underpinning the observed structural and functional organ modifications.

Critically, this study’s longitudinal design allowed for the assessment of sustained metabolic impact one year following surgery, providing more reliable data on long-term physiological adaptation rather than transient postoperative fluctuations. The findings underscore the dynamic but persistent nature of the metabolic recalibration prompted by weight loss interventions.

This landmark research was detailed in Abstract 261206, titled “Evaluation of organic metabolic profiling alternation assessed by [18F]FDG PET/CT in obese patients before and after bariatric surgery,” and presented at the Society of Nuclear Medicine and Molecular Imaging’s 2026 Annual Meeting. The collaborative effort included experts in nuclear medicine, endocrinology, surgery, and biomedical imaging, reflecting the multidisciplinary challenges inherent in obesity treatment research.

In conclusion, this pioneering work spotlights the immense potential of whole-body PET/CT imaging as a transformative modality for understanding and optimizing metabolic health post-bariatric surgery. By mapping the metabolic trajectory across organ systems, clinicians and researchers gain a powerful vantage point to decipher obesity’s complex biology and tailor interventions for maximal therapeutic benefit. This integrated imaging strategy heralds a new era in metabolic medicine, one where precision and personalization drive superior patient outcomes across diverse obesity phenotypes.

Subject of Research: Metabolic changes and organ-level remodeling after bariatric surgery assessed by whole-body 18F-FDG PET/CT imaging.

Article Title: Evaluation of organic metabolic profiling alternation assessed by [18F]FDG PET/CT in obese patients before and after bariatric surgery.

News Publication Date: Not explicitly provided; related to Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

Web References:

• Link to Abstract
• SNMMI Website

Image Credits: Courtesy of Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Keywords: bariatric surgery, 18F-FDG PET/CT, metabolic imaging, obesity, organ metabolism, molecular imaging, personalized medicine, laparoscopic sleeve gastrectomy, one-anastomosis gastric bypass, metabolic remodeling, glucose metabolism, multimodal imaging.

Some effects can be traced to chemical signals inside appetite neurons.

In a small clinical trial, researchers at the Ohio State University found that a tomato juice rich in lycopene and soy isoflavones lowered several proteins linked to chronic inflammation, raising hopes for food-based therapies.

The post Tomato-Soy Drink May Help Fight Chronic Inflammation in Adults with Obesity appeared first on Sci.News: Breaking Science News.